Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rimegepant for acute migraine in children and adolescents
2024-512743-23-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Planned start Aug 2021; status: authorised.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-512743-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512743-23-00.